Simulations Plus

Simulations Plus EBITDA per Employee

The EBITDA per Employee of Simulations Plus (SLP) as of Sep 27, 2026 is -333,627.36 USD. In the previous year, EBITDA per Employee was 28,919.81 USD — a change of -1,253.63% (lower).

EBITDA per Employee

-333,627.36USD

YoY

-1,253.63%

Last updated:

EBITDA per Employee of Simulations Plus is 2026 -333,627.36 USD. EBITDA per Employee of Simulations Plus was 2025 28,919.81 USD. It decreases by -1,253.63% lower compared to the previous year.

The Simulations Plus EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
48,574.47 USD
Jan 1, 2019
50,226.42 USD
Jan 1, 2020
54,740.57 USD
Jan 1, 2021
53,080.19 USD
Jan 1, 2022
70,334.91 USD
Jan 1, 2023
41,155.66 USD
Jan 1, 2024
28,919.81 USD
Jan 1, 2025
-333,627.36 USD
The Simulations Plus EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-333,627.36USD-1,253.63%
28,919.81USD-29.73%
41,155.66USD-41.49%
70,334.91USD+32.51%
53,080.19USD-3.03%
54,740.57USD+8.99%
50,226.42USD+3.40%
48,574.47USD+24.61%
38,982.47USD+14.28%
34,112.29USD+23.48%
27,625.13USD+31.92%
20,940.43USD—
Access this data via the Eulerpool API

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

EBITDA per Employee of Simulations Plus is -333,627.36 USD in 2026.

EBITDA per Employee of Simulations Plus changed from 28,919.81 USD to -333,627.36 USD, representing a -1,253.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Simulations Plus historically and in real time.

Access this data via the Eulerpool API

Workforce — Simulations Plus

All Key Metrics — Simulations Plus